Weekly RSV Vaccination Dashboard

Adults 60+ RSV Vaccination Coverage

RSV vaccination coverage estimates among adults 75 years and older and 60─74 years with high-risk conditions for RSV are based on data from CDC's National Immunization Survey─Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report. Data and charts are available here.

As of November 2, 2024, among adults ≥75 years:

• An estimated 40.1% (95% Confidence Interval: 37.3%─42.9%) reported having ever received an RSV vaccine.
  • An additional 7.1% (4.7%─9.5%) reported they definitely will get a vaccine,
• Vaccination coverage varied by poverty status, health insurance status, urbanicity, race and ethnicity, disability status, and presence of a chronic medical condition.
• Additional RSV vaccination data by demographic characteristics at the national level and overall estimates by jurisdiction are available.

As of November 2, 2024, among adults 60─74 years with a high-risk condition for RSV:

• An estimated 32.0% (27.6%─36.5%) reported having ever received an RSV vaccine.
  • An additional 13.5% (8.6%─18.5%) reported they definitely will get a vaccine.
• Vaccination coverage varied by disability status, health insurance status, poverty status, and race and ethnicity.
• Additional RSV vaccination data by demographic characteristics at the national level and overall estimates by jurisdiction are available.

Adult RSV Vaccinations Administered

IQVIA measures RSV vaccinations administered at retail pharmacies and American Medical Association (AMA) physicians' medical offices for adults 75 years and older, based on healthcare claims data. Data and charts are available here.

• During August 12, 2023, through October 19, 2024, among adults ≥75 years:
  • An estimated ~5.20 million doses of RSV vaccine were administered in retail pharmacies. Of these, an estimated 704,882 doses were administered since August 4, 2024.
  • An estimated 104,048 doses of RSV vaccine were administered in physicians’ medical offices. Of these, an estimated 13,708 doses were administered since August 4, 2024.

Pregnant Persons RSV Coverage

Estimates of RSV vaccination coverage for pregnant persons 18─49 years are calculated using data from CDC's Vaccine Safety Datalink (VSD). VSD data includes electronic health records data from ten integrated health systems. Data and charts are available here.

• As of November 2, 2024, among persons who were pregnant and at least 32 weeks gestation since September 1, 2024, overall coverage with the RSV vaccine was 31.1%.
• Vaccination coverage was highest among non-Hispanic Asian (43.7%) pregnant persons and lowest among non-Hispanic Black (21.2%) pregnant persons.

Monthly Nirsevimab Coverage and Intent for Infants

Monthly nirsevimab coverage and intent estimates reported by females age 18─49 years with infants <8 months during the RSV season (born since April 1, 2024) are based on data from CDC's National Immunization Survey─Adult COVID Module. Estimates of nirsevimab coverage and intent are based on respondent self-report. Data and charts are available here.

• As of September 2024, among females with an infant born since April 1, 52.7% reported that they would definitely get nirsevimab for their infant.